LÓPEZ JARAMILLO, JOSÉ PATRICIO

Preferred name

Main Affiliation

Facultad de Ciencias de la Salud Eugenio Espejo

CENIEC - Grupo de Investigación de Enfermedades Crónicas

Web Site

Google Scholar

ORCID

0000-0002-9122-8742

Scopus Author ID

7004478068

Now showing 1 - 10 of 38

Some of the metrics are blocked by your
consent settings
The association of basal insulin treatment versus standard care with outcomes in anti‐GAD positive and negative subjects: A post‐hoc analysis of the ORIGIN trial
(Wiley, 2018-10-03)
Kåre I. Birkeland
;
Valdemar Grill
;
Cecilie Wium
;
Matthew J. McQueen
;
LOPEZ JARAMILLO, JOSÉ PATRICIO
<jats:p>We compared cardiovascular and other outcomes in patients with dysglycaemia with or without anti‐glutamic acid dehydrogenase (GAD) antibodies participating in the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial. Of the 12 537 participants, 8162 had anti‐GAD measured at baseline and 267 were anti‐GAD positive. The effects of insulin glargine versus standard care and of n‐3 fatty acids supplements versus placebo were compared by testing the interaction of the treatment effects and anti‐GAD status. The effect of glargine on development of new diabetes was assessed in participants without previous diabetes at baseline. The overall incidence of outcomes did not differ between anti‐GAD positive and anti‐GAD negative subjects. The incidence of the composite of cardiovascular death, non‐fatal myocardial infarction, or non‐fatal stroke did not differ between anti‐GAD positive participants randomized to insulin glargine or to standard care, with a hazard ratio (HR) (95% confidence interval [CI]) of 0.80 (0.44‐1.44) or in anti‐GAD negative participants with a HR of 1.07 (0.96‐1.20) (P for interaction = 0.20).</jats:p>
Scopus© Citations 6
Some of the metrics are blocked by your
consent settings
Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries
(Ovid Technologies (Wolters Kluwer Health), 2021-06)
Isabelle Johansson
;
Philip Joseph
;
Kumar Balasubramanian
;
John J.V. McMurray
;
Lars H. Lund
<jats:sec> <jats:title>Background:</jats:title> <jats:p>Poor health-related quality of life (HRQL) is common in heart failure (HF), but there are few data on HRQL in HF and the association between HRQL and mortality outside Western countries.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>We used the Kansas City Cardiomyopathy Questionnaire–12 (KCCQ-12) to record HRQL in 23 291 patients with HF from 40 countries in 8 different world regions in the G-CHF study (Global Congestive Heart Failure). We compared standardized KCCQ-12 summary scores (adjusted for age, sex, and markers of HF severity) among regions (scores range from 0 to 100, with higher score indicating better HRQL). We used multivariable Cox regression with adjustment for 15 variables to assess the association between KCCQ-12 summary scores and the composite of all-cause death, HF hospitalization, and each component over a median follow-up of 1.6 years.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p> The mean age of participants was 65 years; 61% were men; 40% had New York Heart Association class III or IV symptoms; and 46% had left ventricular ejection fraction ≥40%. Average HRQL differed between regions (lowest in Africa [mean± SE, 39.5±0.3], highest in Western Europe [62.5±0.4]). There were 4460 (19%) deaths, 3885 (17%) HF hospitalizations, and 6949 (30%) instances of either event. Lower KCCQ-12 summary score was associated with higher risk of all outcomes; the adjusted hazard ratio (HR) for each 10-unit KCCQ-12 summary score decrement was 1.18 (95% CI, 1.17–1.20) for death. Although this association was observed in all regions, it was less marked in South Asia, South America, and Africa (weakest association in South Asia: HR, 1.08 [95% CI, 1.03–1.14]; strongest association in Eastern Europe: HR, 1.31 [95% CI, 1.21–1.42]; interaction <jats:italic>P</jats:italic> <0.0001). Lower HRQL predicted death in patients with New York Heart Association class I or II and III or IV symptoms (HR, 1.17 [95% CI, 1.14–1.19] and HR, 1.14 [95% CI, 1.12–1.17]; interaction <jats:italic>P</jats:italic> =0.13) and was a stronger predictor for the composite outcome in New York Heart Association class I or II versus class III or IV (HR 1.15 [95% CI, 1.13–1.17] versus 1.09 [95% CI, [1.07–1.11]; interaction <jats:italic>P</jats:italic> <0.0001). HR for death was greater in ejection fraction ≥40 versus <40% (HR, 1.23 [95% CI, 1.20–1.26] and HR, 1.15 [95% CI, 1.13–1.17]; interaction <jats:italic>P</jats:italic> <0.0001). </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>HRQL is a strong and independent predictor of all-cause death and HF hospitalization across all geographic regions, in mildly and severe symptomatic HF, and among patients with preserved and reduced ejection fraction.</jats:p> </jats:sec> <jats:sec> <jats:title>Registration:</jats:title> <jats:p> URL: <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov">https://www.clinicaltrials.gov</jats:ext-link> ; Unique identifier: NCT03078166. </jats:p> </jats:sec>
Scopus© Citations 273
Some of the metrics are blocked by your
consent settings
2024 Latin American Society of Hypertension guidelines on the management of arterial hypertension and related comorbidities in Latin America
(Ovid Technologies (Wolters Kluwer Health), 2025-01-03)
Ramiro Sánchez
;
Antonio Coca
;
Dora I. Molina de Salazar
;
Luis Alcocer
;
Dagnovar Aristizabal
Hypertension is responsible for more than two million deaths due to cardiovascular disease annually in Latin America (LATAM), of which one million occurs before 70 years of age. Hypertension is the main risk factor for cardiovascular morbidity and mortality, affecting between 20 and 40% of LATAM adults. Since the publication of the 2017 LASH hypertension guidelines, reports from different LATAM countries have confirmed the burden of hypertension on cardiovascular disease events and mortality in the region. Many studies in the region have reported and emphasized the dramatically insufficient blood pressure control. The extremely low rates of awareness, treatment, and control of hypertension, particularly in patients with metabolic disorders, is a recognized severe problem in LATAM. Earlier implementation of antihypertensive interventions and management of all cardiovascular risk factors is the recognized best strategy to improve the natural history of cardiovascular disease in LATAM. The 2024 LASH guidelines have been developed by a large group of experts from internal medicine, cardiology, nephrology, endocrinology, general medicine, geriatrics, pharmacology, and epidemiology of different countries of LATAM and Europe. A careful search for novel studies on hypertension and related diseases in LATAM, together with the new evidence that emerged since the 2017 LASH guidelines, support all statements and recommendations. This update aims to provide clear, concise, accessible, and useful recommendations for health professionals to improve awareness, treatment, and control of hypertension and associated cardiovascular risk factors in the region.
Scopus© Citations 28
Some of the metrics are blocked by your
consent settings
Control y tratamiento de la hipertensión arterial: Programa 20-20
(Publicidad Permanyer, SLU, 2019-03)
Juan Felipe Gómez
;
Paul Anthony Camacho
;
José López-López
;
LOPEZ JARAMILLO, JOSÉ PATRICIO
Scopus© Citations 15
Some of the metrics are blocked by your
consent settings
Survey of knowledge for diagnosing and managing prediabetes in Latin-America: cross-sectional study
(Springer Science and Business Media LLC, 2019-12)
Jennifer Garay
;
Paul A. Camacho
;
Jose Lopez-Lopez
;
Juliana Alvernia
;
Marcela Garcia
<jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Prediabetes has been proposed as a risk factor for the development of type 2 diabetes mellitus (DM2) and cardiovascular disease (CVD). Despite the clinical importance of prediabetes, little is known about the level of knowledge, beliefs and barriers to screening and treating prediabetes amongst care health providers in Latin America. The aim of the present survey was to evaluate the knowledge and beliefs about prediabetes amongst in Latin American health care providers.</jats:p> </jats:sec><jats:sec> <jats:title>Methodology</jats:title> <jats:p>In a cross-sectional study, we adapted the written survey designed by the Johns Hopkins University group, and applied it to health care providers across Latin America during three meetings, in 2017, and with physicians from primary care centers in Bucaramanga, Colombia convened in 2017. The survey consisted of questions under four headings, diabetes screening, management of prediabetes, pharmacological treatment—metformin use, and demographic information. We perform a descriptive analysis to determine the differences in responses between different medical specialties.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>The majority of the care providers that answered the survey were Colombian physicians, 54.5% of respondents had 10 years or more since completing their training and more women responded. Only 9.5% identified the 12 prediabetes risk factors described in the literature. The most common risk factor identified was a family history of diabetes, followed by overweight, a sedentary lifestyle and dyslipidemia, while ethnicity was the risk factor least commonly. 47.1% answered that laboratory tests to detect prediabetes are fasting glucose and HbA1C, 82.5% correctly identified fasting plasma glucose as the best test, 35.9% correctly responded that to the recommended weight loss goal is 5 to 7% and 49.1% that 150 min is considered the minimum level of physical activity per week. 78% agreed that the identification and treatment of prediabetes is important. 56% believed that patients with prediabetes progress more rapidly to diabetes and 40.6% considered that metformin could reduce the risk of diabetes in patients already diagnosed with prediabetes.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>These results demonstrate that there are important gaps in the knowledge of the diagnosis, clinical implications and management of prediabetes amongst Latin America health providers.</jats:p> </jats:sec>
Scopus© Citations 14
Some of the metrics are blocked by your
consent settings
Single-pill combination therapy is the standard of care for hypertension, but it is time for the next step: Implementation
(Elsevier BV, 2024-12)
Jose P. Lopez-Lopez
;
LOPEZ JARAMILLO, JOSÉ PATRICIO
The GMRx2 trial1 in adults with high blood pressure (BP) demonstrated that after 12 weeks, a low-dose single-pill combination of telmisartan, amlodipine, and indapamide significantly reduced BP levels compared to several dual combinations (telmisartan with amlodipine, telmisartan with indapamide, or amlodipine with indapamide). Adverse events did not differ between the groups. This novel therapeutic option could improve high BP control
Some of the metrics are blocked by your
consent settings
The positive impact of the Life's Essential 8 in the prevention of incident heart failure
(Oxford University Press (OUP), 2025-02-08)
LOPEZ JARAMILLO, JOSÉ PATRICIO
;
LOPEZ FLECHER, MAVEL ESTEFANIA
;
Jose P Lopez-Lopez
Heart failure (HF) prevalence is increasing rapidly, particularly in middle- and low-income countries, contributing to considerable treatment costs and weakening their health systems.1 Individually, cardiovascular risk factors are associated with a higher risk of developing HF. For example, the NHANES I study reported that smoking is an independent risk factor for incident HF, apart from coronary artery disease (population attributable fraction = 17%).2 A recent meta-analysis showed that hypertension is associated with a 71% increase in the risk of HF and that a 20 mmHg increase in systolic blood pressure is associated with a 28% increase in HF risk.3 Similarly, a pooled analysis of 61 prospective studies on blood pressure and mortality from HF reported a hazard ratio (HR) of 0.53 [95% confidence interval (CI): 0.48–0.59] for a 20 mmHg lower systolic blood pressure.4 However, few studies have examined the combination and the effect of the trajectory, the burden of lifestyles, and the control of risk factors in large observational studies.
Scopus© Citations 1
Some of the metrics are blocked by your
consent settings
Pharmacological Treatment of Hypertension: Effects in Endothelial Function
(Bentham Science Publishers Ltd., 2018-08)
Leonardo Cobos-Segarra
;
LOPEZ JARAMILLO, JOSÉ PATRICIO
;
Carlos Ponte-Negretti CI
;
Raul Villar
;
Ernesto Penaherrera
<jats:sec> <jats:title /> <jats:p>The vascular endothelium plays an important role to maintain the functional integrity of the cardiovascular system. The synthesis and secretion of substances with biological activity such as prostacyclin and NO give endothelium the vasodilator, antithrombotic, and antiatherosclerotic properties. Endothelial dysfunction participates in the genesis of HTA, but also hypertension produces endothelial damage. The major class of antihypertensive drugs has beneficial effects in the recuperation of the endothelial function, actions that are contributing to explain the impact of the adequate control of HTA in the reduction of CV events.</jats:p> </jats:sec>
Scopus© Citations 5
Some of the metrics are blocked by your
consent settings
Diet and Clinical Outcomes in a Heart Failure Population
(Elsevier BV, 2026-04)
Joseph, Philip
;
Dehghan, Mahshid
;
Ezekowitz, Justin A.
;
Miller, Victoria
;
Lanas, Fernando
Scopus© Citations 2
Some of the metrics are blocked by your
consent settings
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
(Elsevier BV, 2018-01)
Stuart J Connolly
;
John W Eikelboom
;
Jackie Bosch
;
Gilles Dagenais
;
Leanne Dyal
Scopus© Citations 388

LÓPEZ JARAMILLO, JOSÉ PATRICIO

Filters

Settings

Sort By

Results per page